G Dolan1, L A Smith, S Collins, J M Plumb. 1. Department of Haematology, QMC Campus, Nottingham University Hospitals, Nottingham, UK. Gerry.Dolan@nottingham.ac.uk
Abstract
OBJECTIVES: To investigate the relationship between time spent in the recommended target International Normalised Ratio (INR) range and the setting and intensity of anti coagulant monitoring, in both treatment-experienced and treatment-naive atrial fibrillation (AF) patients receiving oral anticoagulation (OAC) therapy for the prevention of ischaemic stroke. RESEARCH DESIGN AND METHODS: Systematic review of published studies on participants with atrial fibrillation on anticoagulation therapy. We compared frequent monitoring (well-controlled, according to a strict protocol) versus infrequent monitoring (frequency representative of routine clinical practice), specialised care versus usual care, and naive versus prior anticoagulant use. Meta-analysis was performed using a random effects model. RESULTS: 36 studies were included, 22 (primary data) of AF patients managed in line with the consensus guidelines target INR range of 2.0-3.0, and 14 studies (secondary data) of mixed patient groups, including AF, with an INR target of 2.0-3.5. Both data sets were combined for sensitivity analysis. Pooled mean time in INR range was 59.1% (95% CI: 55.5, 62.8%) and 64.3% (95% CI: 60.5, 68.0%) for infrequent monitoring and frequent monitoring, respectively. Significantly more time was spent in range in specialist care settings compared to usual care: +11.3% (95% CI: 0.1-21.7%). Naive OAC users spent less time in range 56.5% (95% CI: 45.5-67.5%) than existing users 61.2% (95% CI: 57.2-65.2%). All of these differences were found to be significant in the sensitivity analyses. CONCLUSIONS: INR control is variable and dependent on monitoring intensity and duration of anticoagulant therapy.
OBJECTIVES: To investigate the relationship between time spent in the recommended target International Normalised Ratio (INR) range and the setting and intensity of anti coagulant monitoring, in both treatment-experienced and treatment-naive atrial fibrillation (AF) patients receiving oral anticoagulation (OAC) therapy for the prevention of ischaemic stroke. RESEARCH DESIGN AND METHODS: Systematic review of published studies on participants with atrial fibrillation on anticoagulation therapy. We compared frequent monitoring (well-controlled, according to a strict protocol) versus infrequent monitoring (frequency representative of routine clinical practice), specialised care versus usual care, and naive versus prior anticoagulant use. Meta-analysis was performed using a random effects model. RESULTS: 36 studies were included, 22 (primary data) of AFpatients managed in line with the consensus guidelines target INR range of 2.0-3.0, and 14 studies (secondary data) of mixed patient groups, including AF, with an INR target of 2.0-3.5. Both data sets were combined for sensitivity analysis. Pooled mean time in INR range was 59.1% (95% CI: 55.5, 62.8%) and 64.3% (95% CI: 60.5, 68.0%) for infrequent monitoring and frequent monitoring, respectively. Significantly more time was spent in range in specialist care settings compared to usual care: +11.3% (95% CI: 0.1-21.7%). Naive OAC users spent less time in range 56.5% (95% CI: 45.5-67.5%) than existing users 61.2% (95% CI: 57.2-65.2%). All of these differences were found to be significant in the sensitivity analyses. CONCLUSIONS: INR control is variable and dependent on monitoring intensity and duration of anticoagulant therapy.
Authors: Stephen E Kimmel; Benjamin French; Jeffrey L Anderson; Brian F Gage; Julie A Johnson; Yves D Rosenberg; Nancy L Geller; Scott E Kasner; Charles S Eby; Jungnam Joo; Michael D Caldwell; Samuel Z Goldhaber; Robert G Hart; Denise Cifelli; Rosemary Madigan; Colleen M Brensinger; Suzanne Goldberg; Robert M Califf; Jonas H Ellenberg Journal: Am Heart J Date: 2013-07-12 Impact factor: 4.749
Authors: Sherrie L Aspinall; Xinhua Zhao; Steven M Handler; Roslyn A Stone; Janine C Kosmoski; Elizabeth A Libby; Susan Dove Francis; David A Goodman; Rebecca D Roman; Heather L Bieber; Jennifer M Voisine; Sean M Jeffery; Charley A Hepfinger; Diane G Hagen; Micki M Martin; Joseph T Hanlon Journal: J Am Geriatr Soc Date: 2010-07-19 Impact factor: 5.562
Authors: Benjamin French; Jungnam Joo; Nancy L Geller; Stephen E Kimmel; Yves Rosenberg; Jeffrey L Anderson; Brian F Gage; Julie A Johnson; Jonas H Ellenberg Journal: Trials Date: 2010-11-17 Impact factor: 2.279